Neurodegenerative Disease Market
Neurodegenerative Disease Market Forecasts to 2032 – Global Analysis By Molecule Type (Small-Molecule Drugs, Biologics and Cell & Gene Therapies), Indication, Drug Class, Route of Administration, End User and By Geography
According to Stratistics MRC, the Global Neurodegenerative Disease Market is accounted for $64.4 billion in 2025 and is expected to reach $118.9 billion by 2032 growing at a CAGR of 9.15% during the forecast period. Neurodegenerative disease refers to a group of disorders characterized by the progressive loss of structure or function of neurons, leading to their gradual death. These conditions affect the brain and nervous system, impairing cognitive, motor, and sensory functions. Common examples include Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis (ALS). The underlying causes often involve abnormal protein accumulation, genetic mutations, oxidative stress, and mitochondrial dysfunction. As neurons cannot regenerate efficiently, these diseases are typically chronic and worsen over time. Neurodegenerative diseases pose significant medical and social challenges due to their complexity and lack of curative treatments.
Market Dynamics:
Driver:
Advances in biomarker & diagnostic technology
Researchers are developing fluid-based and imaging biomarkers to identify early-stage pathology in Alzheimer’s, Parkinson’s, and ALS. Integration with AI and machine learning is improving diagnostic accuracy and disease stratification. Pharmaceutical companies are using biomarkers to optimize trial design and therapeutic targeting. Companion diagnostics are gaining traction across precision neurology pipelines. These capabilities are propelling innovation in early intervention and personalized care.
Restraint:
Complex disease biology & heterogeneity
Many conditions involve multifactorial pathogenesis, including genetic, environmental, and inflammatory components. Disease progression varies widely across individuals, complicating trial endpoints and treatment response. Lack of validated animal models and translational biomarkers slows preclinical research. Regulatory bodies require robust evidence for efficacy and safety in heterogeneous populations. These challenges continue to hinder drug development and platform scalability.
Opportunity:
Rising healthcare spending & awareness
Governments are funding national dementia strategies and aging-related research programs. Public campaigns are improving awareness and reducing stigma around cognitive decline and neurological disorders. Hospitals are expanding memory clinics and neurorehabilitation centers to meet rising demand. Investment in digital health and remote monitoring is supporting long-term care and disease management. These trends are fostering growth across prevention, diagnosis, and therapeutic innovation.
Threat:
Limited diagnostic access in low-resource settings
Many regions lack trained neurologists, imaging infrastructure, and molecular testing capabilities. Rural and underserved populations face delays in diagnosis and limited access to specialized care. Cost and availability of PET scans, CSF assays, and genetic testing remain barriers in emerging markets. Fragmented referral pathways and low public awareness further degrade care quality. These constraints continue to hamper equity and outcomes across global neurodegenerative ecosystems.
Covid-19 Impact:
The pandemic disrupted clinical trials, diagnostics, and long-term care for neurodegenerative patients worldwide. Lockdowns and resource reallocation delayed therapy access and disease monitoring. However, post-pandemic recovery strategies have emphasized resilience and digital transformation in neurology care. Telemedicine, remote cognitive assessments, and digital biomarkers gained traction across aging populations. Public awareness of neurological health increased during the crisis, influencing policy and research priorities. These shifts are accelerating investment in infrastructure, innovation, and patient-centric care models.
The alzheimer’s disease segment is expected to be the largest during the forecast period
The alzheimer’s disease segment is expected to account for the largest market share during the forecast period due to its high prevalence, diagnostic complexity, and therapeutic innovation. Pharmaceutical firms are launching monoclonal antibodies and disease-modifying therapies targeting amyloid and tau pathology. Investment in early detection and risk stratification is rising across aging populations. Integration with digital cognitive tools and fluid biomarkers is improving screening and monitoring. Governments are funding dementia research and care coordination programs.
The cell & gene therapies segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the cell & gene therapies segment is predicted to witness the highest growth rate as curative approaches gain traction across rare and progressive neurodegenerative conditions. Developers are using viral vectors, stem cells, and gene editing platforms to restore neuronal function and halt disease progression. Regulatory bodies are offering expedited review and conditional approvals for breakthrough therapies. Investment in manufacturing scale-up and delivery platforms is improving readiness and affordability. Partnerships between biotech firms, hospitals, and payers are supporting access and reimbursement models.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share due to its advanced research infrastructure, regulatory engagement, and aging demographics. The United States and Canada host major neurology centers, clinical trial networks, and patient advocacy organizations. FDA programs such as Fast Track and Breakthrough Therapy Designation are supporting innovation and market entry. Investment in biomarker development and precision neurology is driving platform expansion. Presence of leading biotech firms and academic institutions is reinforcing leadership.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as healthcare modernization, aging populations, and policy reform converge. Countries like China, Japan, India, and South Korea are scaling neurology diagnostics and therapy access across urban and rural regions. Government-backed programs are supporting dementia screening, public awareness, and infrastructure development. Regional biotech firms are launching cell and gene therapies tailored to population-specific indications. Demand for affordable and scalable solutions is rising across public and private healthcare systems. These trends are accelerating regional growth across neurodegenerative disease ecosystems.
Key players in the market
Some of the key players in Neurodegenerative Disease Market include AbbVie Inc., Amneal Pharmaceuticals LLC, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., UCB S.A., Biogen Inc., Eli Lilly and Company, Johnson & Johnson, Eisai Co., Ltd., Lundbeck A/S and Denali Therapeutics Inc.
Key Developments:
In January 2025, AbbVie exercised its first opt-in under the collaboration with Capsida Biotherapeutics, securing rights to a gene therapy program for neurodegenerative diseases. The decision followed promising primate data showing effective delivery of AbbVie’s therapeutic payload to the brain using Capsida’s engineered AAV capsids, while minimizing off-target effects in the liver and dorsal root ganglia.
In September 2023, Amneal launched IPX203 in the U.S. following FDA approval for Parkinson’s disease. The extended-release formulation demonstrated superior “on-time” versus immediate-release carbidopa-levodopa in Phase 3 trials, offering improved symptom control and dosing convenience for patients with advanced Parkinson’s.
Molecule Types Covered:
• Small-Molecule Drugs
• Biologics
• Cell & Gene Therapies
Indications Covered:
• Alzheimer’s Disease
• Parkinson’s Disease
• Huntington’s Disease
• Amyotrophic Lateral Sclerosis (ALS)
• Multiple Sclerosis (MS)
• Spinal Muscular Atrophy (SMA)
• Other Indications
Drug Classes Covered:
• N-Methyl-D-Aspartate (NMDA) Receptor Antagonists
• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Dopamine Agonists & Inhibitors
• Cholinesterase Inhibitors
• Monoclonal Antibodies
• Gene & RNA-Based Therapies
• Other Drug Classes
Route of Administrations Covered:
• Oral
• Injectable
• Transdermal
• Intranasal
End Users Covered:
• Hospitals & Clinics
• Research & Academic Institutes
• Pharmaceutical & Biotech Companies
• Patient Advocacy Groups
• Other End-Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Neurodegenerative Disease Market, By Molecule Type
5.1 Introduction
5.2 Small-Molecule Drugs
5.3 Biologics
5.4 Cell & Gene Therapies
6 Global Neurodegenerative Disease Market, By Indication
6.1 Introduction
6.2 Alzheimer’s Disease
6.3 Parkinson’s Disease
6.4 Huntington’s Disease
6.5 Amyotrophic Lateral Sclerosis (ALS)
6.6 Multiple Sclerosis (MS)
6.7 Spinal Muscular Atrophy (SMA)
6.8 Other Indications
7 Global Neurodegenerative Disease Market, By Drug Class
7.1 Introduction
7.2 N-Methyl-D-Aspartate (NMDA) Receptor Antagonists
7.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
7.4 Dopamine Agonists & Inhibitors
7.5 Cholinesterase Inhibitors
7.6 Monoclonal Antibodies
7.7 Gene & RNA-Based Therapies
7.8 Other Drug Classes
8 Global Neurodegenerative Disease Market, By Route of Administration
8.1 Introduction
8.2 Oral
8.3 Injectable
8.4 Transdermal
8.5 Intranasal
9 Global Neurodegenerative Disease Market, By End User
9.1 Introduction
9.2 Hospitals & Clinics
9.3 Research & Academic Institutes
9.4 Pharmaceutical & Biotech Companies
9.5 Patient Advocacy Groups
9.6 Other End-Users
10 Global Neurodegenerative Disease Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 AbbVie Inc.
12.2 Amneal Pharmaceuticals LLC
12.3 Boehringer Ingelheim GmbH
12.4 F. Hoffmann-La Roche Ltd.
12.5 Merck & Co., Inc.
12.6 Novartis AG
12.7 Pfizer Inc.
12.8 Teva Pharmaceutical Industries Ltd.
12.9 UCB S.A.
12.10 Biogen Inc.
12.11 Eli Lilly and Company
12.12 Johnson & Johnson
12.13 Eisai Co., Ltd.
12.14 Lundbeck A/S
12.15 Denali Therapeutics Inc.
List of Tables
1 Global Neurodegenerative Disease Market Outlook, By Region (2024-2032) ($MN)
2 Global Neurodegenerative Disease Market Outlook, By Molecule Type (2024-2032) ($MN)
3 Global Neurodegenerative Disease Market Outlook, By Small-Molecule Drugs (2024-2032) ($MN)
4 Global Neurodegenerative Disease Market Outlook, By Biologics (2024-2032) ($MN)
5 Global Neurodegenerative Disease Market Outlook, By Cell & Gene Therapies (2024-2032) ($MN)
6 Global Neurodegenerative Disease Market Outlook, By Indication (2024-2032) ($MN)
7 Global Neurodegenerative Disease Market Outlook, By Alzheimer’s Disease (2024-2032) ($MN)
8 Global Neurodegenerative Disease Market Outlook, By Parkinson’s Disease (2024-2032) ($MN)
9 Global Neurodegenerative Disease Market Outlook, By Huntington’s Disease (2024-2032) ($MN)
10 Global Neurodegenerative Disease Market Outlook, By Amyotrophic Lateral Sclerosis (ALS) (2024-2032) ($MN)
11 Global Neurodegenerative Disease Market Outlook, By Multiple Sclerosis (MS) (2024-2032) ($MN)
12 Global Neurodegenerative Disease Market Outlook, By Spinal Muscular Atrophy (SMA) (2024-2032) ($MN)
13 Global Neurodegenerative Disease Market Outlook, By Other Indications (2024-2032) ($MN)
14 Global Neurodegenerative Disease Market Outlook, By Drug Class (2024-2032) ($MN)
15 Global Neurodegenerative Disease Market Outlook, By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists (2024-2032) ($MN)
16 Global Neurodegenerative Disease Market Outlook, By Selective Serotonin Reuptake Inhibitors (SSRIs) (2024-2032) ($MN)
17 Global Neurodegenerative Disease Market Outlook, By Dopamine Agonists & Inhibitors (2024-2032) ($MN)
18 Global Neurodegenerative Disease Market Outlook, By Cholinesterase Inhibitors (2024-2032) ($MN)
19 Global Neurodegenerative Disease Market Outlook, By Monoclonal Antibodies (2024-2032) ($MN)
20 Global Neurodegenerative Disease Market Outlook, By Gene & RNA-Based Therapies (2024-2032) ($MN)
21 Global Neurodegenerative Disease Market Outlook, By Other Drug Classes (2024-2032) ($MN)
22 Global Neurodegenerative Disease Market Outlook, By Route of Administration (2024-2032) ($MN)
23 Global Neurodegenerative Disease Market Outlook, By Oral (2024-2032) ($MN)
24 Global Neurodegenerative Disease Market Outlook, By Injectable (2024-2032) ($MN)
25 Global Neurodegenerative Disease Market Outlook, By Transdermal (2024-2032) ($MN)
26 Global Neurodegenerative Disease Market Outlook, By Intranasal (2024-2032) ($MN)
27 Global Neurodegenerative Disease Market Outlook, By End User (2024-2032) ($MN)
28 Global Neurodegenerative Disease Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
29 Global Neurodegenerative Disease Market Outlook, By Research & Academic Institutes (2024-2032) ($MN)
30 Global Neurodegenerative Disease Market Outlook, By Pharmaceutical & Biotech Companies (2024-2032) ($MN)
31 Global Neurodegenerative Disease Market Outlook, By Patient Advocacy Groups (2024-2032) ($MN)
32 Global Neurodegenerative Disease Market Outlook, By Other End-Users (2024-2032) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We offer complimentary customization of up to 15% with every purchase. To share your customization requirements, feel free to email us at info@strategymrc.com or call us on +1-301-202-5929. .
Please Note: Customization within the 15% threshold is entirely free of charge. If your request exceeds this limit, we will conduct a feasibility assessment. Following that, a detailed quote and timeline will be provided.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
